myNEO is involved in several collaborative industrial projects and joint ventures, teaming up with industry-leaders within oncology. In such a collaborative approach, myNEO actively joins forces with companies possessing technology that is compatible with the myNEO platform to deliver novel or personalised validated targets. In addition, academic partnerships allow myNEO to contribute to high-level research that tackles different complex multidisciplinary challenges. Ongoing innovation projects focus on optimising the myNEO technology to improve the specificity and sensitivity of tumour-specific alteration and neoantigen detection.